Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1770 views | HTML 2682 views | ?
Víctor García1, Maribel Lara-Chica1, Irene Cantarero1, Olov Sterner2, Marco A. Calzado1, Eduardo Muñoz1
1Maimónides Biomedical Research Institute of Córdoba, Reina Sofía University Hospital, Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain
2Department of Science, Centre for Analysis and Synthesis, Lund University, Lund, Sweden
Marco A. Calzado, e-mail: [email protected]
Eduardo Muñoz, e-mail: [email protected]
Keywords: galiellalactone, cancer, cell cycle, ATM/ATR, CHK1
Received: September 11, 2015 Accepted: November 26, 2015 Published: December 14, 2015
Galiellalactone (GL) is a fungal metabolite that presents antitumor activities on prostate cancer in vitro and in vivo. In this study we show that GL induced cell cycle arrest in G2/M phase, caspase-dependent apoptosis and also affected the microtubule organization and migration ability in DU145 cells. GL did not induce double strand DNA break but activated the ATR and ATM-mediated DNA damage response (DDR) inducing CHK1, H2AX phosphorylation (fH2AX) and CDC25C downregulation. Inhibition of the ATM/ATR activation with caffeine reverted GL-induced G2/M cell cycle arrest, apoptosis and DNA damage measured by fH2AX. In contrast, UCN-01, a CHK1 inhibitor, prevented GL-induced cell cycle arrest but enhanced apoptosis in DU145 cells. Furthermore, we found that GL did not increase the levels of intracellular ROS, but the antioxidant N-acetylcysteine (NAC) completely prevented the effects of GL on fH2AX, G2/M cell cycle arrest and apoptosis. In contrast to NAC, other antioxidants such as ambroxol and EGCG did not interfere with the activity of GL on cell cycle. GL significantly suppressed DU145 xenograft growth in vivo and induced the expression of fH2AX in the tumors. These findings identify for the first time that GL activates DDR in prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.